People · Operator
Named in public records as an officer, director or promoter · active 2014–2025 · Software / Tech, Other Technology, Other, Healthtech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Motive Technologies, Inc. | — | Software / Tech | Series D+ | $408.0M | $1.4B | 2025 |
| Kong Inc. | — | Other Technology | Series C | $224.4M | $725.9M | 2024 |
| Databook Labs, Inc. | — | Software / Tech | Series C | $71.4M | $968.9M | 2021 |
| Zeno Moto Corp | — | Other | Series A | $24.3M | $27.9M | 2024 |
| Blackbird Health, Inc. | — | Healthtech | Series B | $22.8M | $176.9M | 2024 |
| Purchasing Platform, Inc. | — | Software / Tech | Series A | $14.7M | $81.0M | 2019 |
| Neurelo, Inc. | — | Other Technology | Series A | $4.3M | $50.8M | 2022 |
| Live Sust Inc. | — | Other Technology | Pre-Seed | $475K | $7.4M | 2022 |
| Push Health, Inc. | — | Other Technology | Pre-Seed | $308K | $13.0M | 2014 |
| Avestor Inc. | — | Other | Pre-Seed | $100K | $1.1M | 2022 |
Chirag Shah at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Chirag Shah on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Martin Casado | 1 | 12 |
| Ilya Fushman | 1 | 11 |
| Tom Peterson | 1 | 10 |
| Devdutt Yellurkar | 1 | 9 |
| Josh Stein | 1 | 9 |
| Somesh Dash | 1 | 8 |
| Lon Chow | 1 | 7 |
| Mike Volpi | 1 | 6 |
| J Sanford Miller | 1 | 5 |
| Joe Kraus | 1 | 5 |
| Elliott Robinson | 1 | 4 |
| Dana Evan | 1 | 4 |
| Gregory Moran | 1 | 4 |
| Aaron Schildkrout | 1 | 4 |
| Alexander Niehenke | 1 | 4 |
| Mark Goldberg | 1 | 4 |
| Adam Block | 1 | 3 |
| Michael Spencer | 1 | 3 |
| Charles Tollinche | 1 | 3 |
| David Bowen | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.